Clinical Trial Update: ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ALRN-6924 in combination with paclitaxel in patients with advanced, unresectable solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ALRN-6924 (MDM2/MDMX dual inhibitor)
• Taxol (paclitaxel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 1 | Status: COMPLETED